Dynamics of hepatitis C under optimal therapy and sampling based analysis
From MaRDI portal
Publication:375585
DOI10.1016/J.CNSNS.2012.12.032zbMATH Open1274.92035arXiv1109.0615OpenAlexW2075346118MaRDI QIDQ375585FDOQ375585
Gaurav Pachpute, Siddhartha P. Chakrabarty
Publication date: 31 October 2013
Published in: Communications in Nonlinear Science and Numerical Simulation (Search for Journal in Brave)
Abstract: We examine two models for hepatitis C viral (HCV) dynamics, one for monotherapy with interferon (IFN) and the other for combination therapy with IFN and ribavirin. Optimal therapy for both the models is determined using the steepest gradient method, by defining an objective functional which minimizes the infected hepatocyte levels, virion population and the side-effects of the drug(s). The optimal therapy for both the models shows an initial period of high efficacy, followed by a gradual decline. The period of high efficacy coincides with a significant decrease in the infected hepatocyte levels as well as viral load, whereas the efficacy drops after liver regeneration through restored hepatocyte levels. The period of high efficacy is not altered significantly when the cost coefficients are varied, as long as the side effects are relatively small. This suggests a higher dependence of the optimal therapy on the model parameters in case of drugs with minimal side effects. We use the Latin hypercube sampling technique to randomly generate a large number of patient scenarios (i.e, model parameter sets) and study the dynamics of each set under the optimal therapy already determined. Results show an increase in the percentage of responders (as indicated by drop in viral load below detection levels) in case of combination therapy as compared to monotherapy. Statistical tests performed to study the correlations between sample parameters and the time required for the viral load to fall below detection level, show a strong monotonic correlation with the death rate of infected hepatocytes, identifying it to be an important factor in deciding individual drug regimens.
Full work available at URL: https://arxiv.org/abs/1109.0615
Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical epidemiology (92C60)
Cited In (7)
- Dynamic analysis and optimal control for a model of hepatitis C with treatment
- Title not available (Why is that?)
- Towards prediction of HCV therapy efficiency
- Observer‐based controller for treatment of hepatitis C infection using fractional order model
- Prediction of long-term treatment outcome in HCV following 24 day PEG-IFN alpha-2b therapy using population pharmacokinetic-pharmacodynamic mixture modeling and classification analysis
- Optimal control of viral infection model with saturated infection rate
- Optimal control of an HIV model with CTL cells and latently infected cells
This page was built for publication: Dynamics of hepatitis C under optimal therapy and sampling based analysis
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q375585)
